Navigation Links
Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
Date:1/20/2008

NEW YORK, Jan. 20 /PRNewswire-USNewswire/ -- A landmark genetic study has identified multiple genes linked to systemic lupus erythematosus (SLE), or lupus, a debilitating autoimmune disease that affects an estimated 1.4 million Americans.

Lupus can affect the joints, kidneys, heart, lungs, brain and blood and occurs in about 31 out of every 100,000 people. Women are nine times more likely than men to develop the condition, which is often difficult to diagnose.

In 2005 the Alliance for Lupus Research (ALR) formed and supported the International Systemic Lupus Erythematosus Genetics (SLEGEN) Consortium, charging scientists with searching for genetic variants that might predispose an individual to developing lupus.

Published in the January 20, 2008, issue of Nature Genetics, initial study results uncovered several genes linked to lupus and underscore the importance of genetic variants in diseases that affect immune function. The findings will ultimately lead to new therapies and earlier diagnosis.

"The SLEGEN study is a model for collaborative genetic research," said Mary Kuntz Crow, M.D., an immunity and inflammation specialist at the Hospital for Special Surgery in New York and 2008 chair of the ALR Scientific Advisory Board. "The ALR approach of supporting investigations targeted toward developing new therapies for people with lupus is unique and meaningful."

Project co-Director Carl Langefeld, Ph.D., added, "These results suggest biologic pathways that help us understand the condition better and suggest additional genetic and non-genetic triggers. In addition, they will help delineate the genetic distinctions between rheumatoid arthritis, lupus and other autoimmune diseases, which could lead to earlier, more accurate diagnoses."

Langefeld, who is director of the Center for Public Health Genomics at Wake Forest University in Winston-Salem, N.C., also noted how satisfying the study results were. "This is one of those things that, at the end of your career, you can look back on and smile because you believe it will make a real difference."

SLEGEN Director John B. Harley, M.D., Ph.D., explained that the study found strong evidence of association with multiple single nucleotide polymorphisms (SNPs) in three genes: ITGAM; KIAA1542; PXK; and at SNP rs10798269, a DNA unit not found within any known gene. SNPs are chromosome locations where a single unit of DNA may vary from one person to another.

The results also showed evidence linking lupus to nine other genes. "I would have been satisfied with finding one gene. The fact that we present 13 strong candidates, supported by data that are 99% accurate is tremendous," added Harley, who heads the Arthritis & Immunology Research Program at the Oklahoma Medical Research Foundation in Oklahoma City.

Researchers studied the DNA of more than 6,700 women, including individuals with lupus, their family members and control subjects. Harley said they scanned the entire genome for more than 317,000 SNPs with the goal of identifying SNPs linked to lupus.

"SLEGEN's purpose is to do the genomics," Harley said. "The mechanism of the disease by which these genes cause lupus will be seized upon by scientists who are expert in those pathways to develop new strategies for prevention and therapy and reduce the burden of suffering this disease causes."

Langefeld said the accomplishments made in the SLEGEN research wouldn't have been possible without the support of ALR. "We simply would not have been able to do it without them."

"We are very pleased to see the findings in print and are grateful that the ALR support for SLEGEN has had such a fruitful outcome," said Joseph E. Craft, M.D., chief of rheumatology at Yale University School of Medicine and former chair of the ALR Scientific Advisory Board.

The Alliance for Lupus Research (ALR) is a national voluntary health organization based in New York City and founded in 1999. Chaired by Robert Wood Johnson IV, it has become the world's largest private source of lupus research funds and has committed $50 million to lupus-specific research projects since its inception. The organization's mission is to find better treatments and ultimately prevent and cure lupus by supporting medical research. Because ALR's Board of Directors pays for all administrative and fundraising costs, 100% of all donations go to support lupus research. For more information, visit http://www.lupusresearch.org.


'/>"/>
SOURCE Alliance for Lupus Research
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
2. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
3. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
4. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
5. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
6. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery
9. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
10. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/22/2017)... Sept. 22, 2017  As the latest Obamacare repeal ... Bill Cassidy (R-LA) and Lindsey Graham ... the medical device industry is in an odd place. ... the 2.3% excise tax on medical device sales passed ... want covered patients, increased visits and hospital customers with ...
(Date:9/19/2017)... , Sept. 19, 2017   ZirMed Inc ., ... analytics, today announced that it has been ranked #1 by ... Black Book™ Rankings 2017 User Survey. ZirMed was recognized ... for large hospitals and medical centers over 200 beds and ... Book,s healthcare technology user survey history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... of the most popular and least understood books in the Holy Scriptures, Revelation. The ... that have baffled scholars for centuries. Many have tossed it off as mere rubbish, ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated ... in breathing. Oral appliances can offer significant relief to about 75 percent of ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):